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Abstract 
Background In patients with heart failure, P-blocker therapy improves left-ventricular function after 3-6 
months of treatment, but effects of such treatment on symptoms and exercise performance are 
inconsistent, and the longer-term effects on death and other serious clinical events remain uncertain. We 
have investigated these issues in a doubleblind, placebo-controlled, randomised trial of the P-adrenergic 
blocker carvedilol (which also has a,-blocking properties). Methods 415 patients with chronic stable heart 
failure were randomly assigned treatment with carvedilol (207) or matching placebo (208). At baseline, 6 
months, and 12 months, we measured left-ventricular ejection fraction, leftventricular dimensions, 
treadmill exercise duration, 6 min walk distance, New York Heart Association (NYHA) class, and specific 
activity scale (SAS) score. Double-blind followup continued for an average of 19 months, during which all 
deaths, hospital admissions, and episodes of worsening heart failure were documented. Findings After 12 
months, left-ventricular ejection fraction had increased by 5.3% (2p 
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Randomised, placebo-controlled trial of carvedilol in patients with 
congestive heart failure due to ischaemic heart disease 
Australia/New Zealand Heart Failure Research Collaborative Group* 
Background In patients with heart failure, P-blocker therapy 
improves left-ventricular function after 3-6 months of 
treatment, but effects of such treatment on symptoms and 
exercise performance are inconsistent, and the longer-term 
effects on death and other serious clinical events remain 
uncertain. We have investigated these issues in a double- 
b l ind,  p lacebo-contro l led,  randomised t r ia l  o f  the  
P-adrenergic blocker carvedilol (which also has a,-blocking 
properties). 
Methods 415 patients with chronic stable heart failure were 
randomly assigned treatment with carvedilol (207) or 
matching placebo (208). A t  baseline, 6 months, and 12  
months, we measured left-ventricular ejection fraction, left- 
ventricular dimensions, treadmill exercise duration, 6 min 
walk distance, New York Heart Association (NYHA) class, 
and specific activity scale (SAS) score. Double-blind follow- 
up continued for an average of 19  months, during which all 
deaths, hospital admissions, and episodes of worsening 
heart failure were documented. 
Findings After 12 months, left-ventricular ejection fraction 
had increased by 5.3% (2p<O,OOOl) and end-diastolic and 
end-systo l ic  d imensions had decreased by 1 . 7  mm 
(2p=0.06) and 3.2 mm (2p=0.001), respectively, in the 
carvedilol group compared with the placebo group. During 
the same period that were no clear changes in treadmill 
exercise duration, 6 min walk distance, NYHA class, or SAS 
score. After 1 9  months, the frequency of episodes of 
worsening heart failure was similar in the carvedilol and 
placebo groups (82 vs 75; relative r isk 1.12 [95% CI  
0.82-1.531) but the rate of death or hospital admission was 
lower in the carvedilol group than in the placebo group (104 
vs 131; relative risk 0.74 [0.57-0.95]). 
Interpretation The beneficial effects of carvedilol on left- 
ventricular function and size were maintained for at least a 
year after the start of treatment, but carvedilol had no effect 
on exercise performance, symptoms, or episodes of  
worsening heart failure. There was an overall reduction in 
events resulting in death or hospital admission, and a year 
of treatment with carvedilol resulted in the avoidance of one 
such serious event among every 12-13 (SE 5) of these 
patients with chronic stable heart failure. 
Lancet 1997; 349 375-80 
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Introduction 
Despite advances in the treatment of congestive heart 
failure, the outlook for many patients with this disorder 
remains poor. In patients with mild or moderate symptoms 
who receive standard treatment including an inhibitor of 
angiotensin-converting enzyme (ACE), the annual rate of 
hospital admission is about 15520% and the mortality rate 
about lo%.' Treatment with P-blockers may have the 
potential to reduce morbidity and mortality in heart failure, 
but there is no unequivocal evidence as yet.z However, 3-6 
months of treatment with a P-blocker has been clearly 
shown to increase left-ventricular ejection fraction by about 
5% (absolute units) in patients with heart failure of 
idiopathicz or ischaemic' aetiology. Such therapy has not 
produced any consistent effects on symptoms or exercise 
performan~e,~'~ and whether longer-term treatment will 
produce clearer benefits for these outcomes or for serious 
morbidity and mortality remains unclear. 
We report here the final results from the Australiamew 
Zealand Heart Failure Research Collaborative Group trial 
of carvedilol in 415 patients with heart failure due to 
ischaemic heart disease. Carvedilol is a P-blocker with 
a,-blocking vasodilator properties and with several other 
potentially advantageous effects, including antioxidant and 
anti-ischaemic propertiesP A planned interim analysis from 
this study after 6 months of follow-up showed an absolute 
increase of 5.2% in left-ventricular ejection fraction, a 
reduction in left-ventricular dimensions, no change in 
exercise performance, and a trend to worsening of 
symptoms of heart failure among patients assigned 
~arvedilol.~ We now provide data on the same outcomes 
after 12 months of follow-up, as well as the risks of death, 
hospital admission, or worsening heart failure during an 
average of 19 months of follow-up. 
Methods 
Pa tien ts 
Participants were recruited to the trial from 20 hospitals in 
Australia and New Zealand. Potentially eligible patients had 
chronic stable heart failure due to ischaemic heart disease (defmed 
as a documented history of myocardial infarction, typical angina, 
an  exercise electrocardiogram positive for ischaemia, or  
angiographic evidence of coronary disease) and a left-ventricular 
ejection fraction by radionuclide ventriculography of less than 
45%, and were of current New York Heart Association (NYHA) 
functional class I1 or I11 or previous NYHA class 11-IV. 
Exclusion criteria included current NYHA class IV; heart rate 
below 50 bpm; sick sinus syndrome; second-degree or third- 
degree heart block; blood pressure below 90 mm Hg systolic or 
above 160/100 mm Hg; treadmill exercise duration less than 
2 min or more than 18 min (modified Naughton protocol); 
coronary event or procedure (myocardial infarction, unstable 
angina, coronary-artery bypass surgery, or coronary angioplasty) 
within the previous 4 weeks; primary myocardial or valvular 
disease; current treatment with a P-blocker, P-agonist, or 
verapamil; insulin-dependent diabetes mellitus; chronic 
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Characteristic Carvedilol group Placebo group 
(11-207) (n.208) 
182 (88%) 
9 1  (44%) 
History 
Previous myocardial infarction 
Previous hospital admission for 
heart failure 
Previous highest NYHA class 
I1 56 (27%) 
IV  92 144%1 




Current NYHA class 
I 
II 
1 1 1  


















Table 1: Selected baseline characteristics of groups 
obstructive airways disease; hepatic disease (serum 
aminotransferase above three times normal); renal impairment 
(serum creatinine >250 pmol/L); or any other life-threatening 
non-cardiac disease. 
Design and study treatment 
Before randomisation, 442 potentially eligible patients began 2 to 
3 weeks of open treatment with carvedilol. After a test dose of 
3.125 mg, treatment began with 3.125 mg twice daily for 1 to 2 
weeks, progressing to 6.25 mg twice daily for a further week, if 
tolerated. The purpose of this open treatment phase was to 
identify patients who could not tolerate a low dose of carvedilol or 
who were unlikely to comply with treatment or follow-up 
requirements. 27 (6%)  patients were withdrawn from the study 
during this phase; the reasons for withdrawal have been reported 
previously.’ 
The 415 compliant patients who tolerated carvedilol 6.25 mg 
twice daily were then randomly assigned, under double-blind 
conditions, continued treatment with carvedilol or matching 
placebo. Randomised allocation was obtained by telephone call to 
the Clinical Trials Research Unit  randomisation service in 
Auckland. Treatment assignment was provided by computer, with 
stratification for clinical centre and a minimisation algorithm5 to 
ensure balance for ejection fraction, treadmill exercise duration, 
and exercise-limiting myocardial ischaemia (termination of 
baseline exercise test because of angina or electrocardiographic 
ST-T changes). There was a 2-5-week dose titration period with 
weekly assessment, the aim being to increase the dose of carvedilol 
to a maximum of 25 mg twice daily (or the equivalent dose of 
matching placebo) or to the highest dose tolerated. Maintenance 
treatment then continued with carvedilol (6.25-25 mg twice daily) 
or matching placebo, with clinical assessments at 5 weeks and 
3 months, then every 3 months for a minimum of 15 months and 
an average of 19 months. 
Study outcomes 
The primary study outcomes were changes in left-ventricular 
ejection fraction, assessed by radionuclide ventriculography, and 
treadmill exercise duration, measured with a modified Naughton 
protocol with 2 min stages. Secondary study outcomes included 
changes in left-ventricular dimensions, submaximum exercise 
performance ( 6  min walk distance‘), and symptoms of heart 
failure described by NYHA class and the specific activity scale 
(SAS),’ and the frequency of death, hospital admission, or 
worsening heart failure. Left-ventricular dimensions were assessed 
by two-dimensional guided M-mode echocardiography, and all 
measurements were made from videotapes (ImageVue, Nova 
Microsonics, Allendale, NJ, USA) at  a central laboratory 
(University of Auckland) by an observer unaware of treatment 
group and according to American Society of Echocardiography 
standards.8 An episode of worsening heart failure was defined as 
any clinically significant deterioration in the patient’s condition 
(for example, an increase in non-study treatment requirements, an 
I 447 eligible patients registered I 
5 patients withdrawn 1 ‘  




27 patients withdrawn 
415 patients randomly assigned 
double-blind treatment 
207 assigned carvediol 
at 6 months 
172 still taking carvedilol 
at 12 months 
157 still taking catvedilol 
1 
177 with data available 
at end of follow-up 
(mean 19 months) 
146 still taking catvedilol 
41  withdrawn. 20 died 
at 6 months 
189 still taking placebo 
at 12 months 
176 with data available 
at end of follow-up 
(mean 19 months) 
152  still taking placebo 
30 withdrawn, 26  died 
Figure 1: Trial profile 
increase in NYHA functional class, hospital admission for 
worsening symptoms of heart failure, or a non-sudden death from 
worsening heart failure). We collected data on the reasons for and 
duration of all episodes of hospital admission and on the causes 
and circumstances of deaths among trial participants. Separate 
analyses of the combined outcome of death or hospital admission 
and of fatal or non-fatal worsening heart failure were planned a 
priori. Data on deaths, hospital admissions, and episodes of 
worsening heart failure were obtained throughout an average of 19 
months of follow-up; measurements for study outcomes were 
made at  baseline and  a t  6 months and 12 months after 
randomisation. 
Statistics 
A sample size of 200-225 patients per group was estimated to 
provide more than 80% power at statistical significance of 0.05 to 
detect: an absolute change in left-ventricular ejection fraction of 
2% or more between the groups (with the assumption of a 
standard deviation of change in ejection fraction of about 6%); 
and a change in treadmill exercise duration of 1 min or more 
between groups (with the assumption of a standard deviation of 
change in treadmill exercise duration of about 3 min). With a 
2 5 3 0 %  annual rate of death or hospital admission,’ such a 
sample size would also provide reasonable power during 18 
months of follow-up to detect any moderate-to-large reduction 
(eg, a third or more) in this combined endpoint; however, it 
would probably be inadequate for the detection of all but an 
extremely large effect of treatment on death alone. 
Principal outcome analyses were by intention to treat .  
Differences between groups from baseline to 12 months in left- 
ventricular ejection fraction, treadmill exercise duration, left- 
ventricular dimensions, 6 min walk distance, blood pressure, and 
heart rate were assessed by two-sample t tests. Each of the 
symptom scales was analysed by xz. Differences between groups in 
376 Vo1349 - February 8, 1997 
the frequency of death or hospital admission and of episodes of 
worsening heart failure were analysed with a Cox proportional 
hazards model.  Probability values for two-tailed tests of 
significance (2p) are given throughout, rounded to one significant 
figure, except for values greater than 0.1 or less than 0.0001. 
Results 
The mean age of the participants at entry to the study was 
67 years, and 80% were men. 70% were classified as being 
NYHA functional class I1 or I11 at the time of 
randomisation, and 43% had previously been class IV 
(table 1). Almost 90% had a history of myocardial 
infarction, and 42% had had a previous hospital admission 
for heart failure. 95% were currently receiving drug 
treatment for the management of heart failure, and 85% 
were receiving ACE-inhibitor therapy. The average left- 
ventricular ejection fraction at entry was 29% (SD 8) and 
the average left-ventricular end-diastolic and end-systolic 
dimensions were 69 mm (10) and 57 mm (11). The 
average treadmill duration was 10.5 min (4), and the 
average 6 min walk distance 392 m (74). Treadmill 
exercise duration was limited by myocardial ischaemia 
(angina or ST-T changes) in 24% of patients. 
Figure 1 shows the flow of patients through the trial. 
Complete data on mortality were available for all 415 
patients throughout follow-up. Other data were available 
for 392 patients at 6 months (97% of survivors), 373 at 12 
months (96% of survivors), and 353 (96% of survivors) at 
the scheduled end of follow-up (between Aug 6, 1994, and 
June 21, 1995; mean 19 months). 361 patients completed 6 
months of study treatment (90% of survivors), 329 
completed 12 months of treatment (85% of survivors), and 
298 (SOYO of survivors) were still on study treatment at the 
scheduled end of follow-up. After 6 months, there was a 
small excess of withdrawals from treatment in the carvedilol 
group (30 71s 13; 2p=0.01), but by the end of follow-up the 
numbers of withdrawals from the two groups were similar 
(41 vs 30; 2p>0.1). 
Among the 298 patients still taking study treatment at 
the end of follow-up, the mean dose was similar in the 
carvedilol and placebo groups (41 mg DS equivalent of 
45 mg daily, 2p>0.1). By the scheduled end of follow-up, 
30% of patients assigned treatment with carvedilol had 
died or were no longer receiving study treatment, 7% were 
taking 12.5 mg daily, 16% 25 mg daily, and 48% 50 mg 
daily. Among those receiving other therapy for heart failure, 
there was no significant change in the mean dose of 
furosemide, captopril, or enalapril from baseline to the 
scheduled end of follow-up. 
From baseline to 12 months, supine and maximum 
exercise heart rates fell by 6.8 bpm and 20.2 bpm, 
respectively (both 2p<0.0001), in the carvedilol group 
compared with the placebo group. Supine and maximum 
exercise blood pressures declined by 5.2/3.7 mm Hg 
(2p=0.008/0.006) and 10-8/3.0 mm Hg (2p<0.0001/0.07) 
respectively, in the carvedilol group compared with the 
placebo group during the same period. The fall in 
maximum exercise-rate/pressure product from baseline to 
12 months was 4201 mm Hg bpm (22%; 2p<0.0001). 
Between the 6-month and 12-month visits, there was no 
evidence of any attenuation of the differences between the 
groups in heart rate or blood pressure (all 2p>0.1, except 
maximum exercise heart rate 2 ~ ~ 0 . 0 8 ) .  
Left-ventricular ejection fraction increased from 28.4% 
at baseline to 33.5% at 12 months among patients assigned 
carvedilol (figure 2). The placebo group showed little 
THE LANCET y,////+z 2 
0 
I I I 
I I 1 
Baskline 6 rndnths 1 2  months 
Figure 2: Changes in left-ventricular ejection fraction and left- 
ventricular dimensions in carvedilol and placebo groups during 
12 months of follow-up 
Values at 6 and 12 months represent mean change from baseline W E ) .  
change; therefore, there was a difference between the 
groups at 12 months of 5.3% (SE 0.7). Left-ventricular 
end-diastolic and end-systolic dimensions were 1.7 mm 
(2p=0.06) and 3.2 m m  (2p=0.001) smaller in the 
carvedilol group than in the placebo group after 12 months 
(figure 2). Between 6 and 12 months, there was no clear 
evidence of any attenuation of the differences between the 
groups in ejection fraction or left-ventricular dimensions 
(all 2p>0.1). 
There was no significant difference between the 
carvedilol and placebo groups in treadmill exercise 
duration at 12 months (mean difference -7 s [95% CI 
I I 
; -0.2 - I 
- 1 5 -  E 
1
5 1 0  - 
5 





5 -  Y 
S .- 
E 
Baseline 6 months 1 2  months 
Figure 3: Changes in maximum (treadmill exercise duration) 
and submaximum (6 min walk distance) exercise performance 
in carvedilol and placebo groups over 12 months of follow-up 
Values at 6 and 12 months represent mean change from baseline ( i S E ) .  
Vo1349 * February 8, 1997 377 
THE LANCET 
% of patients in treatment group 
Baseline to 6 months 
Improved No change Worse Improved No change Worse 
Baseline to 12 months 
- ------ 
NYHA 
Carvedilol 23 65 12 26 58 16 
Placebo 28 67 6 28 58 13 
SAS 
Carvedilol 16 67 17 21 63 16 
Placebo 26 64 10 30 56 14 
- ------ 
Table 2: Changes in severity of symptoms of heart failure 
-50 to 361; figure 3) or in 6 min walk distance (mean 
difference -3 m [- 18 to 1 11. The outcomes were similar 
in the subgroup of patients whose baseline exercise test was 
limited by myocardial ischaemia. 
After 6 months of follow-up, there were significant 
trends towards less improvement and more frequent 
worsening of the NYHA class (2p=0.05) and SAS score 
(2p=0.02) in the carvedilol group compared with the 
placebo group (table 2). However, at 12 months there were 
no significant differences between the groups in either scale 
(both 2p>0.1). At that time, 56-63% of patients showed no 
change in their scores from baseline, 21-30% showed an 
improvement, and 13-16% showed a worsening. The 
results were similar when the analyses were restricted to the 
patients in NYHA class I1 or I11 at entry to the study 
(70%). 
During an average of 19 months of follow-up, 46 (1 1 %) 
patients died and 219 (53%) were admitted to hospital. For 
the combined endpoint of death or hospital admission 
(figure 4), there was a 26% reduction in risk among 
patients assigned treatment with carvedilol (104 carvedilol 
vs 131 placebo; relative risk 0.74 [95% CI 0.57-0.951, 
2 ~ ~ 0 . 0 2 ) .  For death alone there was no significant 
difference in risk between the groups (20 carvedilol ZJS 26 
placebo; 0.76 rO.42-1.361, 2p>O.1) and for hospital 
admission alone there was a 23% reduction in risk, of 
borderline statistical significance (99 carvedilol vs 120 
placebo; 0.77 [0.59-1.0], 2 ~ ~ 0 . 0 5 ) .  No single cause of 
death or hospital admission appeared to be primarily 
associated with the overall reduction in risk observed in the 
carvedilol group (table 3). 
56 (13%) patients were admitted to hospital for heart 
failure, and 157 (38%) experienced an episode of 
worsening heart failure. Although there were fewer (but not 
significantly) admissions for heart failure in the carvedilol 
Carvedilol Placebo Relative risk 
(n.208) (11-207) (95% CI) -- 
Cause of death 
Heart failure 14 15 0.92 (0.45-1.91) 
Sudden* 10 11 0.90 (0.38-2.11) 
Non-sudden 4 4 0.99 (0.25-3.96) 
Myocardial infarction 4 5 0.79 (0.21-2.94) 
All cardiovascular deaths 18 20 0.89 (0.47-1.68) 
Non-cardiovascuiar deaths 2 6 0.32 (0.07-1.60) 
Ail deaths 20 26 0.76 (0.42-1.36) _ _ _ -  
Cause of hospital admission?. 
Heart faiiure 23 33 0.68 (0.40-1.17) 
lschaemic heart disease 25 34 0.70 (0.42-1.18) 
Other cardiovascuiar disease 40 38 1.07 (0.68-1.66) 
Ail cardiovascular disease 70 83 0.82 (0.59-1.12) 
Non-cardiovascular disease 51 69 0.70 (0.49-1.01) 
All admissions 99 120 0.77 10.59-1.001 
'Within 24 h of onset of new symptoms or death of a previously symptom-free patient. 
tSubtotals and totai do not equal sum of individual causes of hospital admissions 
since each patient can contribute only one hospital admission to a single analysis, but 
patients with several hospital admissions for different causes may contribute to more 
than one analysis. 
Table 3: Causes of death and hospital admission during an 
average of 19 months of follow-up 
Death or hospital admission 




Patients at risk 
207Carvedilol 151 1 2 7  103 
208 Placebo 146 112 7 7  
n 
0 - J  I I I 
0 6 12 
Time (months) 
Worsening heart failure 
18 
Placebo fn=75) 
I Carvedilol (n=82) 
OE44 
Patients at risk 
207Carvedilol 162 142 120 
208 Placebo 1 7 0  139 120 
I I I 
0 ', 6 12 18 
Time (months) 
Figure 4: Death or hospital admission and episodes of 
worsening heart failure in carvedilol and placebo groups during 
an average of 19 months of follow-up , 
than the placebo group (table 3), the total frequency of 
episodes of worsening heart failure (figure 4) was similar in 
the two groups (82 carvedilol and 75 placebo; relative risk 
1.12 [95% CI 0.82-1.531, 2p>0'1). 
Discussion 
We have found that in patients with chronic stable heart 
failure due to ischaemic heart disease, the effects of 
carvedilol on left-ventricular function were maintained for 
at least a year from the start of treatment, with no apparent 
loss of the initial short-term improvement. These effects 
were achieved against a background of standard drug 
therapy for heart failure, including ACE inhibitors for more 
than 80% of patients. The increase in left-ventricular 
ejection fraction and the decrease in left-ventricular 
dimensions suggest a sustained improvement in intrinsic 
myocardial function. Treatment with carvedilol did not, 
however, confer any changes in maximum or submaximum 
exercise performance or in the severity of symptoms 
assessed by NYHA class or SAS score. The absence of any 
functional or symptomatic improvement after 12 months is 
consistent with the absence of any clear difference in the 
overall frequency of worsening heart failure during 19 
months of treatment and follow-up. Thus, there was an 
apparent dissociation of changes in left-ventricular function 
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from changes in exercise capacity and symptoms of heart 
failure. Whether there are benefits of @-blocker therapy for 
these outcomes in other subgroups of patients with heart 
failure remains uncertain. There have been reports of such 
benefits in some, though not all, trials of @-blockers in 
patients with idiopathic cardiomyopathyz and in other 
trials among patients with more severe heart fail~re.~.” 
Further randomised studies among such patients would 
help to show more clearly whether there are subgroups of 
patients whose symptoms could benefit from treatment 
with P-blockers. 
In addition to improving left-ventricular function, 
treatment with carvedilol was also associated with a lower 
overall risk of serious clinical events resulting in death or 
hospital admission. During the follow-up period, such 
events occurred in 63% of the placebo group and in 50% of 
the carvedilol group. This difference represents the 
avoidance each year of one serious event among every 
12-13 patients treated with carvedilol (with 95% CI 
confidence limits ranging from the avoidance of one event 
in every seven patients to the avoidance of one event in 
every 60 patients). This improvement did not seem to be 
associated with one particular type of event-there were 
similar trends for deaths and hospital admissions, and for 
all serious cardiovascular events, ischaemic-heart-disease 
events, heart-failure-related events, and non-cardiovascular 
events. The degree to which the benefits of carvedilol are a 
consequence of P-blockade per se or of the other 
potentially beneficial properties of this agent remains 
uncertaim4 The overall treatment effect on death or 
hospital admission (ie, a reduction in risk of 26%) is, 
however, consistent with the results of several other trials of 
@-blockers in patients with heart failure, mostly of 
idiopathic aetiologyz~ll~’z as well as results from the limited 
subgroups of patients with heart failure in the trials of 
P-blockers in patients with myocardial infar~tion.”,’~ 
A combined analysis of four trials in the USA of patients 
with heart failure15 also found a reduction in deaths and 
hospital admissions after treatment with carvedilol. The 
reduction in risk of hospital admission in those studies was 
similar to that in our study, but the reduction in mortality 
in the US trials (relative risk 0.35 [95% CI 0.20-0.611) 
after 6.5 months appeared to be larger than ours (relative 
risk 0.76 [0.42-1.36]). However, the number of deaths in 
each of the four US trials of carvedilol was small, and the 
combined total of only 53 deaths was similar to the total 
number in our study. The apparent difference between the 
US studies and our study in the effects of carvedilol on 
survival was not statistically significant (2p for 
heterogeneity >0.1) and could therefore have occurred by 
chance rather than as a consequence of any particular 
difference in selection of patients or study design. 
Trials of carvedilol so far have recorded too few deaths, 
even in combination, for reliable calculation of the size of 
the effect of this drug on survival in patients with heart 
failure. However, if a reduction in mortality of 25% or 
more (as suggested by these studies) were confirmed in 
larger-scale, longer-term trials of carvedilol, there would be 
important implications for the management of patients with 
heart failure. Even among patients with mild symptoms, 
one death would be avoided each year among every few 
dozen patients treated. Given this possible benefit and the 
findings, from this and other trials, that the drug is well 
tolerated when introduced at low doses, carvedilol has the 
potential to become part of standard therapy for many 
patients with heart failure. However, the present clinical 
trial experience with carvedilol is too limited for this 
treatment to be widely recommended for the management 
of patients with heart failure. Only 1658 patients have been 
studied for an average of 10 months in eight randomised 
trials of this d r ~ g . ~ J ~ ~ ’ ~ - ’ ~  T h  ese studies were principally 
designed to investigate the effects of carvedilol on left- 
ventricular function and exercise performance. Trials of 
appropriately larger size (ie, several thousand patients) and 
duration (ie, several years), designed to investigate the 
effects of carvedilol on survival are now required to show 
whether this drug can be recommended as first-line therapy 
for heart failure, together with ACE inhibitors. 
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Fa m i I ia I in t rac ra n i a I a neu rysms 
Antti Ronkainen, Juha Hernesniemi, Matti Puranen, Lea Niemitukia, Ritva Vanninen, Markku Ryynanen, 
Helena Kuivaniemi, Gerard Tromp 
Summary 
Background We set out to  determine the prevalence of 
incidental intracranial aneurysms in first-degree relatives 
aged 30 years or  more o f  people w i th  in t racrania l  
aneurysms, and t o  see i f  polycystic kidney d isease 
contributes t o  the aggregation of  famil ial  intracranial 
aneurysms . 
Methods 91 families with two or more affected members 
had previously been identified from a 14 year series of 
1 1 5 0  in t racrania l  aneurysm pat ients  t reated a t  the 
University Hospital of Kuopio, Finland. Magnetic resonance 
angiography was used as a preliminary screening method, 
followed by conventional four-vessel angiography to verify 
suspected aneurysms. Participants were also screened for 
polycystic kidneys by ultrasonography. 
Findings Inc identa l  aneurysms were detected in  40 
individuals: 38 of 438 individuals from 85 families without 
polycystic kidney disease or other diagnosed heritable 
disorders, and two  of 22 individuals from six families 
known to have polycystic kidney disease. The crude and 
age-adjusted prevalence o f  inc identa l  in t racran ia l  
aneurysms among screened first-degree relatives was 8.7 
(SE 1.3)% (95% CI 6.2-11.7) and 9.1 (1.4)% (6.2-11.7), 
respect ive ly ,  fo r  t h e  fami l ia l  group and t h e  crude 
prevalence for the polycystic kidney group was 9.1 (6.1)% 
Interpretation Our results demonstrate a high prevalence of 
incidental in tracran ia I aneurysms among f i rst-degree 
relatives aged 30 years or older o f  patients with the 
condition and indicate that the risk of having an aneurysm 
is about four t imes higher for a close relative than for 
someone from the general population. Also, polycystic 
kidney disease families are a small fraction of the familial 
intracranial aneurysm families. 
lancet 1997; 349: 380-84 
Departments of Neurosurgery (A Ronkainen MD, J Hernesniemi MD), 
Clinical Radiology (M Puranen MD, L Niemitukia MD, R Vanninen MD), 
and Obstetrics and Gynaecology (M Ryynanen MD), 
University Hospital of Kuopio, PL 1777, 70210 Kuopio, Finland; and 
Center for Molecular Medicine and Genetics, Wayne State 
University School of Medicine, Detroit, MI, USA (G Tromp PhD, 
H Kuivaniemi MD), 
Correspondence to: Dr Antti Ronkainen 
(1.1-29.2). 
Introduction 
About one-quarter of cerebrovascular deaths are due to 
subarachnoid haemorrhage (SAH) .' SAH is a devastating 
disease, since about half the patients die due to primary 
bleeding or to subsequent complications, and many of the 
survivors will need extended rehabilitaton to continue an 
independent life. This poor outcome has changed little 
during the past two or three decades, even though the 
treatment of SAH has become a daily routine in 
neurosurgical centres.* The economic impact of SAH is 
severe because it most often affects patients in their 40s 
and 50s during their most productive years.' As many as 
80-90% of SAHs are caused by ruptured intracranial 
aneurysms (IAs).~-~ Up to 60% of individuals who 
experience aneurysmal SAH will die before hospital 
admission6 After hospital admission, about one-third will 
die, about one-sixth will recover with a severe disabilty, 
about one-sixth will have some disability, and about one- 
third will have excellent outcome.6 Increasing experience 
in treating ruptured IAs, either with advanced 
microsurgical or with endovascular techniques, has 
resulted in improved outcomes for elective surgery of 
unruptured IAS.',~ The per case mortality for treatment of 
unruptured IAs involving elective surgery is below 2%, 
whereas the per case mortality for treatment of ruptured 
aneurysms that involves emergency surgery may exceed 
30% with mortality due to surgery rarely exceeding 30%.7,9 
In addition, the techniques of endovascular surgery such 
as selective occlusion of aneurysms with detachable 
balloons and metallic coils have the promise of reducing 
surgical complications and mortality even further.* Given 
the strikingly different outcomes, it is evident that treating 
IAs before rupture would save lives. 
Screening the population at large for the presence of IAs 
is not feasible, but identification of groups with increased 
risk may make screening feasible. Familial aggregation of 
IAs has been observed and IAs are often associated with 
the autosomal dominant form of polycystic kidney disease 
(PCKD).l0 6-20% of IA cases may be familial with two or 
more confirmed IA cases in the same family in the absence 
of any signs of other hereditary disorder~."-'~ Younger age 
of onset, presence of IAs among twins, and the fact that in 
siblings the age of onset is closer than expected by chance 
support the hypothesis that familial intracranial aneurysms 
(FIA), in the absence of other predisposing heritable 
disorders, are a distinct disease entity.I5 l6 
The risk of at least two individuals in a family being 
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